Natural products targeting hepatitis B virus X protein and HBx-associated pathways in HBV-related hepatocellular carcinoma: mechanisms and therapeutic potential.
Natural products show promise in targeting HBx and associated pathways in HBV-related HCC, but clinical validation is needed.
Where it sits
this study against the rest of the melanotan i (mt-i) corpusSummary and findings
This review evaluates the role of the hepatitis B virus X protein (HBx) in HBV-related hepatocellular carcinoma (HCC) progression and examines the therapeutic potential of natural products targeting HBx. It analyzes literature from the past decade, including in vitro, in vivo, and clinical evidence. The review highlights natural products that suppress HBV replication and influence HBx-driven oncogenic pathways.
Abstract
<h4>Context</h4>Hepatocellular carcinoma (HCC), largely driven by chronic hepatitis B virus (HBV) infection, remains a major global health challenge with limited curative options in advanced stages. The hepatitis B virus X protein (HBx) is a multifunctional viral oncoprotein that plays a central role in HBV persistence and hepatocarcinogenesis by disrupting transcriptional regulation, DNA repair, apoptosis, and immune responses.<h4>Objective</h4>This review aims to evaluate the role of HBx in HBV‑related HCC progression and to examine the therapeutic potential of natural products that directly target HBx and indirectly modulate HBx‑driven antiviral and oncogenic pathways.<h4>Methods</h4>A comprehensive literature analysis was conducted focusing on studies published over the past decade, including <i>in vitro</i>, <i>in vivo</i>, and clinical evidence addressing HBx-mediated mechanisms and the pharmacological effects of bioactive natural products, including plant‑derived phytochemicals and non‑plant natural compounds.<h4>Results</h4>Accumulating evidence indicates that some natural products suppress HBV replication by reducing HBx expression, promoting HBx degradation, or limiting HBx‑dependent cccDNA transcription, whereas others primarily influence biological pathways associated with HBx‑driven hepatocarcinogenesis, including migration, invasion, fibrosis, metabolic reprogramming, and apoptosis resistance.<h4>Conclusion</h4>Natural products represent a promising multi-target therapeutic strategy for HBV-related HCC by intervening in HBx-driven oncogenic processes. Future studies should focus on mechanistic validation, standardization of bioactive compounds, and well-designed clinical trials to support their translational application as adjunctive or alternative therapies.
Background
Hepatocellular carcinoma (HCC) is a significant global health issue, primarily driven by chronic hepatitis B virus (HBV) infection. The hepatitis B virus X protein (HBx) is a key viral oncoprotein involved in HBV persistence and the development of HCC. This study is important as it explores potential therapeutic strategies using natural products to target HBx and its associated pathways.
Methods
The study is a literature review analyzing research from the past decade. It includes in vitro, in vivo, and clinical studies focusing on HBx-mediated mechanisms and the effects of natural products. The review examines plant-derived phytochemicals and non-plant natural compounds.
Results
The review found that certain natural products can suppress HBV replication by reducing HBx expression, promoting its degradation, or limiting cccDNA transcription. Other compounds affect biological pathways related to HBx-driven hepatocarcinogenesis, such as cell migration, invasion, fibrosis, metabolic reprogramming, and resistance to apoptosis.
Interpretation
The findings suggest that natural products could offer a multi-target therapeutic strategy for HBV-related HCC. However, the clinical significance remains uncertain due to the preclinical nature of most evidence. The review calls for further mechanistic studies and clinical trials to validate these potential therapies.
Key findings
- Natural products reduce HBx expression and promote HBx degradation.
- Some compounds limit HBx-dependent cccDNA transcription.
- Natural products influence HBx-driven pathways like migration and invasion.
- Evidence includes in vitro, in vivo, and clinical studies.
- Future studies need mechanistic validation and clinical trials.
Limitations
- Review-based, no new experimental data
- Primarily preclinical evidence
- Need for clinical trials
- Lack of standardization of bioactive compounds